Thank you for standing by, and welcome to WeRide's Fourth Quarter and Full Year 2025 Earnings Conference Call. Please note that today's event is being recorded. [Operator Instructions] Please note ...
MetaOptics Ltd (Catalist: 9MT) (“MetaOptics” or the “Company”, and together with its subsidiaries, the “Group”) recently ...
Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 ...
Vietnam Investment Review on MSN
MetaOptics advances growth strategy and leadership transition
SINGAPORE, March 20, 2026 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group") recently announced a series of strategic ...
Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...
Inside a diseased cell, the genes are in chaos. Some are receiving signals to overproduce a protein. Others are reducing ...
WeRide Inc. ("WeRide” or the "Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the fourth quarter and full ...
Mahindra Holidays & Resorts India Limited, India's leading leisure hospitality company, today announced the launch of two new ...
Tata Consultancy Services, a global leader in IT services, consulting, and business solutions, and Swissport International Limited, a global leader in aviation services, have extended and expanded ...
This manuscript explores the dynamic behaviors of Pol II and Pol III puncta that encompass the SL1 and 5S genes, following up on the authors' prior studies on ATTF-6. The authors show that ATTF-6 is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results